Evidence map›Paper›PMID 34992225›Full record

ArticleInternational journal of impotence research2023

Trends in testosterone prescription amongst medical specialties: a 5-year CMS data analysis.

Isabelle V Carter, Michael J Callegari, Tarun K Jella, Amr Mahran, Thomas B Cwalina, Wade Muncey, Aram Loeb, Nannan Thirumavalavan

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of impotence research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Isabelle V CarterCase Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-2176-3715
Michael J CallegariUrology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. mcallegarimd@gmail.com.ORCID http://orcid.org/0000-0001-7839-2305
Tarun K JellaCase Western Reserve University School of Medicine, Cleveland, OH, USA.
Amr MahranUrology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Thomas B CwalinaCase Western Reserve University School of Medicine, Cleveland, OH, USA.
Wade MunceyUrology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Aram LoebUrology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Nannan ThirumavalavanUrology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
University Hospitals of Cleveland · USUniversity School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Testosterone Therapy (TTh) trends have changed as a result of clinical research and market forces over the past several years. Understanding the trends or preferences regarding testosterone prescriptions remains unknown. Our objective was to assess both regional and national trends in TTh prescriptions amongst medical specialties within the United States between 2013 and 2017. Publicly available data from the Center for Medicare and Medicaid Services (CMS) Part D Prescriber database with regards to TTh prescriptions across a 5-year span (January 1, 2013-December 31, 2017) were analyzed. TTh therapies were consolidated into four categories: Topical, Oral, Injection and Pellet. Statistical analysis utilizing R 4.0.2 was performed on the resulting data. Trends in prescription modality claim count and cost were plotted over the study period while statistical analysis evaluated associations between TTh modality and medical specialist. We found that Endocrinologists and Urologists prescribed topical testosterone more than all other specialties (60.4% and 53.5%, respectively), while Family and Internal medicine physicians were more likely to prescribe injections (59.82% and 50.69%, respectively). Oral and pellet testosterone were rarely prescribed across all specialties. In conclusion, the wide variation in modalities of testosterone prescriptions illustrates an opportunity for treatment guidelines to be streamlined across all specialists to improve patient outcomes.

Indexed as

MedicineTestosteroneAgedCenters for Medicare and Medicaid Services, U.S.HumansMedicarePrescriptionsUnited StatesTestosterone

Identifiers

PMID34992225
OpenAlexW4205954193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.